3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
5
Observational
3
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
1
Pathologic Processes
1
Oligodendroglioma
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Glioma
1
Disease Attributes
1
Astrocytoma
1
Interventions
3-Iodobenzylguanidine
9
TIC10 compound
3
vorasidenib
1
ulixertinib
1
tucatinib
1
tovorafenib
1
rindopepimut
1
pembrolizumab
1
pegfilgrastim
1
paclitaxel-Angiopep-2 conjugate
1
omburtamab I-131
1
mogamulizumab
1
mirdametinib
1
gallium maltolate
1
fluorodopa F 18
1
efineptakin alfa
1
carbon-11 methionine
1
avapritinib
1
Vorinostat
1
Vaccination
1
Proton Pump Inhibitors
1
Potassium Iodide
1
OKN 007
1
Methionine
1
Ketoconazole
1
Ipilimumab
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Fenretinide
1
Eflornithine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
vorasidenib
×
CNS
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing